About Trinity Life Sciences
Trinity Life Sciences has built its reputation as one of the most trusted commercial strategy and analytics partners in the life sciences industry, working exclusively with pharmaceutical, biotechnology, and medical device companies to inform critical business decisions across the product lifecycle.
Founded in 1996 and headquartered in Waltham, Massachusetts, Trinity operates as a specialised consultancy and analytics firm rather than a drug developer. Its core value lies in helping biopharma clients answer high-stakes commercial questions: whether a therapy will find a viable market, how to price and position it, and how to launch it effectively in competitive or rare-disease settings.
The firm's capabilities span market access and pricing strategy, brand and portfolio planning, forecasting, patient analytics, and real-world evidence. It is particularly well regarded for its work in rare diseases and specialty therapeutics, where small patient populations and complex reimbursement landscapes demand highly precise commercial intelligence. Trinity also supports early-stage asset valuation and business development assessments, making it a resource across both pre-launch and in-market phases.
Trinity serves a broad client base that includes global pharmaceutical majors, mid-size specialty companies, and emerging biotechs. Its integrated approach, combining primary market research, proprietary data assets, and consulting expertise, differentiates it from pure-play research vendors or strategy firms that lack deep life sciences domain knowledge.
Further information is available at trinitylifesciences.com.
